Abstract | PURPOSE: METHODS: After 2-4 weeks of observation, patients were randomized 2:1 to receive oral TAC-302 200 mg or placebo twice daily for 12 weeks. The primary endpoint was detrusor contraction strength, estimated by bladder contractility index ( BCI) for males and projected isovolumetric pressure 1 (PIP1) for females. Secondary endpoints included changes in bladder voiding efficiency (BVE) and safety. RESULTS: Seventy-six patients were included (TAC-302, n = 52; placebo, n = 24). The mean (standard deviation [SD]) BCI for males was 64.6 (16.6) at baseline and 75.2 (21.1) at week 12 (p < 0.001) with TAC-302 (n = 27), and 61.3 (16.6) and 60.5 (16.7) (p = 0.82) with placebo (n = 11). The respective mean (SD) PIP1 for females was 18.8 (6.6) and 29.4 (9.4) (p < 0.001) with TAC-302 (n = 15), and 20.6 (7.5) and 25.5 (9.6) (p = 0.14) with placebo (n = 7). TAC-302 significantly increased BCI in males and BVE in both sexes. TAC-302 efficacy on OAB was not clearly shown. The incidences of adverse events (AEs), serious AEs, and AEs leading to dose interruption were similar between groups; no adverse drug reactions occurred. CONCLUSION: Considering the significant effects on BCI in males and BVE in both sexes, TAC-302 may benefit patients with DU. REGISTRATION: ClinicalTrials.gov Identifier NCT03175029 registered 6/5/2017.
|
Authors | Masaki Yoshida, Momokazu Gotoh, Osamu Yokoyama, Hidehiro Kakizaki, Tomonori Yamanishi, Osamu Yamaguchi |
Journal | World journal of urology
(World J Urol)
Vol. 40
Issue 11
Pg. 2799-2805
(Nov 2022)
ISSN: 1433-8726 [Electronic] Germany |
PMID | 36205739
(Publication Type: Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article)
|
Copyright | © 2022. The Author(s). |
Chemical References |
|
Topics |
- Male
- Female
- Humans
- Urinary Bladder, Overactive
(drug therapy, complications)
- Urinary Bladder, Underactive
(complications)
- Urodynamics
- Urination
- Double-Blind Method
- Treatment Outcome
|